Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$55.37
-$0.28(-0.50%)
At close: 4:00 PM EDT
$55.37
-$0.28(-0.50%)
Day’s Range― - ―
52-Week Range$33.76 - $57.57
Previous CloseN/A
Volume1.84M
Average Volume (3M)2.53M
Market Cap
$13.40B
Enterprise Value$13.83K
Total Cash (Recent Filing)$839.38M
Total Debt (Recent Filing)$165.93M
Price to Earnings (P/E)16.6
Beta0.93
Next Earnings
Nov 03, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding247,781,700
10 Day Avg. Volume2,048,214
30 Day Avg. Volume2,530,490
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$51.92Price Target Upside-6.23% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)3.5
Revenue Forecast (FY)$2.55B
Bulls Say, Bears Say
Bulls Say
Cabozantinib Franchise Growth And Market LeadershipThe established cabozantinib franchise continues to expand through prescription growth and leading market share in RCC and NET. This commercial scale supports recurring product revenue, strengthens physician familiarity, and provides a durable base for funding pipeline development.
Strong Cash Generation And Conservative LeverageHigh cash conversion and minimal leverage give Exelixis substantial financial flexibility. Strong internally generated funds can support clinical programs, business development, shareholder returns, and resilience without relying heavily on external financing.
Zanzalintinib Pipeline AdvancementZanzalintinib offers a potential second commercial franchise and reduces long-term dependence on cabozantinib. Multiple pivotal studies across CRC, NET, RCC, and other indications create several paths for future growth and extend the company’s oncology platform.
Bears Say
Lowered Revenue Guidance And Slower NET AdoptionThe slower NET launch indicates that near-term growth depends on patient-treatment timing in an indolent and heterogeneous setting. A prolonged ramp could constrain revenue expansion and make commercial forecasts less predictable despite underlying franchise strength.
Elevated Gross-to-net DeductionsHigher rebates, assistance, and channel deductions reduce the revenue retained from each prescription. If these pressures persist, reported product growth may lag prescription and market-share gains, limiting margin leverage and the economic benefit of commercial expansion.
Clinical And Regulatory Uncertainty For Pipeline ExpansionPipeline value depends on successful trial interpretation, regulatory outcomes, labeling, and market adoption. Subgroup concerns and competitive or IP challenges could delay approvals, narrow commercial opportunity, or require additional evidence and investment.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $33.76 and its highest was $57.57 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $13.40B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Nov 03, 2026 which is in 70 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 05, 2026. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.853 by $0.057.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.89.
How many shares outstanding does Exelixis have?
Exelixis has 247,781,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.91 in its last earnings report, beating expectations of $0.853. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.92 (-6.23% Downside)
$51.92 (-6.23% Downside)
Blogger Sentiment
Bullish
EXEL Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 443.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. (EXEL) is a biotechnology company focused on discovering, developing, and commercializing medicines, primarily in oncology. The company’s core products are small-molecule therapeutics, including its marketed cancer therapy cabozantinib (sold as CABOMETYX and COMETRIQ), and it also advances additional oncology candidates through clinical development.
EXEL Company Deck
EXEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects strong commercial performance, healthy profitability and a well-advanced zanzalintinib development program with multiple pivotal trials and a pending NDA/PDUFA. These positive fundamentals are tempered by a modestly slower-than-expected NET ramp that prompted a $50 million downward adjustment to revenue guidance, higher gross-to-net expectations (30%–31%), and some clinical/regulatory uncertainties (STELLAR-303 subgroup result, 505(b)(2) dynamics). On balance, the company’s execution, cash position (~$1.4B), active share repurchases, and deep pipeline milestones outweigh the near-term headwinds, supporting a constructive outlook while acknowledging short-term risks.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$51.92
▼(-6.23% Downside)
Technical Analysis
Ownership Overview
3.57% Insiders
26.42% Mutual Funds
23.13% Other Institutional Investors
17.31% Public Companies and
Individual Investors